Advances in Pharmacy Practice and Medication Use among Patients

A special issue of Healthcare (ISSN 2227-9032). This special issue belongs to the section "Medication Management".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 1787

Special Issue Editor


E-Mail Website
Guest Editor
Department of Bromatology, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, Mickiewicza 2D Street, 15-222 Białystok, Poland
Interests: dietary supplements; pharmacy; food quality assessment; nutrition assessment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

A concept that has recently gained importance in terms of using drugs among patients is broadly understood as pharmaceutical care. It covers such areas as the safety and effectiveness of pharmacotherapy.

We are pleased to invite you to submit publications regarding advances in pharmacy practice and drug use among patients.

The aim of this Special Issue entitled "Advances in Pharmacy Practice and Medication Use among Patients" is to summarize the latest knowledge in the field of pharmacy, including supplementation and setting new directions for research on the safety of pharmacotherapy.

Original research articles and reviews are welcome in this Special Issue.

I look forward to receiving your contributions.

Dr. Anna Puścion-Jakubik
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacy
  • medicines
  • safety and effectiveness of therapy
  • pharmaceutical care
  • dietary supplements

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

14 pages, 3771 KiB  
Systematic Review
The Impact of Statins on Disease Severity and Quality of Life in Patients with Psoriasis: A Systematic Review and Meta-Analysis
by Abdulsalam Mohammed Aleid, Ghadah Almutairi, Rudhab Alrizqi, Houriah Yasir Nukaly, Jomanah Jamal Alkhanani, Deemah Salem AlHuraish, Hawazin Yasser Alshanti, Yaser Sami Algaidi, Hanan Alyami, Awatif Alrasheeday, Bushra Alshammari, Kawthar Alsaleh and Abbas Al Mutair
Healthcare 2024, 12(15), 1526; https://doi.org/10.3390/healthcare12151526 - 31 Jul 2024
Viewed by 1421
Abstract
Background: Psoriasis, a chronic autoimmune condition, imposes significant burdens on patients’ well-being. While corticosteroid medications are commonly used, their prolonged use presents risks. Statins, known for their immunoregulatory and anti-inflammatory properties, have emerged as potential alternatives. Previous reviews indicated that statins might improve [...] Read more.
Background: Psoriasis, a chronic autoimmune condition, imposes significant burdens on patients’ well-being. While corticosteroid medications are commonly used, their prolonged use presents risks. Statins, known for their immunoregulatory and anti-inflammatory properties, have emerged as potential alternatives. Previous reviews indicated that statins might improve psoriasis symptoms but showed inconsistent results and lacked meta-analyses that generated pooled effect estimates. Therefore, this study addresses this gap by providing a comprehensive overview of the impact of statins on psoriasis severity and quality of life (QoL) for patients with psoriasis. Methods: A thorough search of four electronic databases (PubMed, Cochrane Central Register of Controlled Trials, Scopus, and Science Direct) was conducted for relevant studies published before April 2024. Results: Seven studies involving 369 patients were included. This meta-analysis showed a statistically significant reduction in PASI scores at week 8 with statin treatment (MD = −1.96, 95% CI [−3.14, −0.77], p = 0.001). However, no statistically significant difference was found between statins and placebo at week 12 (MD = 0.19, 95% CI [−0.18, 0.55]). Additionally, DLQI scores indicated a significant improvement in quality of life with statins compared to placebo (MD = −3.16, 95% CI [−5.55, −0.77]). Conclusions: Statins can improve disease severity and quality of life in psoriasis patients, suggesting the potential benefits of statin therapy. However, further research is needed to determine the optimal treatment duration, address outcome heterogeneity, and explore additional benefits such as cholesterol and triglyceride reduction. Full article
(This article belongs to the Special Issue Advances in Pharmacy Practice and Medication Use among Patients)
Show Figures

Figure 1

Back to TopTop